What chemotherapy would you consider to treat platinum resistant high grade serous ovarian cancer in patients with a low grade MDS from prior platinum/PARPi?

Before making a recommendation to this patient, a basic understanding of treatment related MDS/AML is needed, along with a clarification of the meaning of “low risk of progression to acute myeloid leukemia (AML)”. My main goal would be to avoid therapy with a demonstrated risk of treatment related M...

In January 2022, I answered this question on Mednet. I was recently asked to update that response, considering current treatment options for platinum-resistant ovarian cancer patients (with a low-grade MDS). Since January 2022, there have been three treatment regimens with FDA approvals for this gro...